elezanumab

Home
Ligands
elezanumab

GtoPdb Ligand ID: 9290

Synonyms: ABT-555 | AE12-1Y-QL

Comment: Elezanumab (ABT-555) is a fully human monoclonal antibody targeting repulsive guidance molecule-a (RGMA), in development as a potential therapy for multiple sclerosis (MS).
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. BLAST peptide anaylsis reveals identical matches with peptides claimed in patent WO2013112922 [2].

Summary
Biological activity
Clinical data
References
Immunopharmacology

Immunopharmacology Comments
Elezanumab (ABT-555) is clinical candidate monoclonal anti-RGMA antibody, that is in Phase 1 development for MS. Inhibition of RGMA is expected to concurrently block autoimmune demyelination and axon injury to reduce severity of MS pathology.

Immunopharmacology Comments

Elezanumab (ABT-555) is clinical candidate monoclonal anti-RGMA antibody, that is in Phase 1 development for MS. Inhibition of RGMA is expected to concurrently block autoimmune demyelination and axon injury to reduce severity of MS pathology.